Verve Therapeutics Inc Forecast, price target & analysts
Verve Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Verve Therapeutics Inc Classifications & Recommendation:
Verve Therapeutics Inc Price Target
| Target Price | $13.52 |
| Price | $11.28 |
| Potential |
19.81%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Verve Therapeutics Inc 2026 .
The average Verve Therapeutics Inc target price is $13.52.
This is
19.81%
register free of charge
$21.00
86.17%
register free of charge
$11.11
1.51%
register free of charge
|
|
| A rating was issued by 14 analysts: 6 Analysts recommend Verve Therapeutics Inc to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verve Therapeutics Inc stock has an average upside potential 2026 of
19.81%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 32.33 | 41.30 |
| 174.91% | 27.76% | |
| EBITDA Margin | -686.39% | -659.62% |
| 62.92% | 3.90% | |
| Net Margin | -614.63% | -536.32% |
| 63.87% | 12.74% |
12 Analysts have issued a sales forecast Verve Therapeutics Inc 2025 . The average Verve Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Verve Therapeutics Inc EBITDA forecast 2025. The average Verve Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Verve Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Verve Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.35 | -2.49 |
| 24.68% | 5.96% | |
| P/E | negative | |
| EV/Sales | 12.31 |
12 Analysts have issued a Verve Therapeutics Inc forecast for earnings per share. The average Verve Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Verve Therapeutics Inc...
Current Verve Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BMO Capital |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| LifeSci Capital |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BMO Capital:
Locked
➜
Locked
|
Jun 27 2025 |
|
Locked
LifeSci Capital:
Locked
➜
Locked
|
Jun 18 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Jun 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 18 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
